Cargando…

Effectiveness and Safety of Sacubitril/Valsartan in Patients with Chronic Kidney Disease—A Real-World Experience

Background: data regarding the effectiveness and safety of sacubitril/valsartan in heart failure and reduced ejection fraction (HFrEF) patients with chronic kidney disease (CKD) are scarse. Objective: to evaluate the effectiveness and safety of sacubitril/valsartan in HFrEF and CKD in a real-world p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pereira, Sara C., Rodrigues, Tiago, Nunes-Ferreira, Afonso, Agostinho, João R., Pinto, Fausto J., Brito, Dulce
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967392/ https://www.ncbi.nlm.nih.gov/pubmed/36835870 http://dx.doi.org/10.3390/jcm12041334

Ejemplares similares

The history and mystery of sacubitril/valsartan: From clinical trial to the real world
por: Zhang, Mingsong, et al.
Publicado: (2023)

Real‐world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany
por: Wachter, Rolf, et al.
Publicado: (2019)

Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)

Antiarrhythmic Effect of Sacubitril-Valsartan: Cause or Consequence of Clinical Improvement?
por: Valentim Gonçalves, António, et al.
Publicado: (2019)

Real-World Usage of Sacubitril/Valsartan in Korea: A Multi-Center, Retrospective Study
por: Park, Jin Joo, et al.
Publicado: (2022)

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
por: Anderson, Sarah L, et al.
Publicado: (2018)

Real-World Safety of Sacubitril/Valsartan in Women and Men With Heart Failure and Reduced Ejection Fraction: A Meta-analysis
por: Nuechterlein, Kaitlin, et al.
Publicado: (2021)

Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF
por: Visco, Valeria, et al.
Publicado: (2022)

Updated insights on dementia‐related risk of sacubitril/valsartan: A real‐world pharmacovigilance analysis
por: Chen, Congqin, et al.
Publicado: (2023)

The efficacy and safety of Sacubitril/Valsartan on pulmonary hypertension in hemodialysis patients
por: Zhao, Cong, et al.
Publicado: (2022)

Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study)
por: Di Lenarda, Andrea, et al.
Publicado: (2023)

Implication of low dose sacubitril/valsartan
por: Imamura, Teruhiko
Publicado: (2021)

Eligibility and Usage of Sacubitril/Valsartan in Korea
por: Kim, Jin-Jin, et al.
Publicado: (2019)

Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real‐world study in Taiwan
por: Chang, Po‐Cheng, et al.
Publicado: (2020)

Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction
por: Polito, Maria Vincenza, et al.
Publicado: (2020)

Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real‐world clinical setting
por: Nordberg Backelin, Charlotte, et al.
Publicado: (2020)

Initial Real-World Practical Experience of Sacubitril/Valsartan Treatment in Japanese Patients With Chronic Heart Failure
por: Nakamura, Makiko, et al.
Publicado: (2021)

Sacubitril/valsartan improves cardiac function in Chinese patients with heart failure: a real‐world study
por: Chen, Wenwen, et al.
Publicado: (2021)

Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real‐world study
por: Wang, Chen, et al.
Publicado: (2023)

Efficacy and safety of sacubitril/valsartan vs. valsartan in patients with acute myocardial infarction: A meta-analysis
por: Yang, Pei, et al.
Publicado: (2022)

Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials
por: Abdin, Amr, et al.
Publicado: (2022)

Insights into implementation of sacubitril/valsartan into clinical practice
por: Martens, Pieter, et al.
Publicado: (2018)

Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018)

Re: Implication of low‐dose sacubitril/valsartan
por: Pandey, Amitabh C., et al.
Publicado: (2021)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
por: Mustafa, Nor Hidayah, et al.
Publicado: (2022)

Effects of Sacubitril/Valsartan on the Renal Resistance Index
por: Gioia, Margherita Ilaria, et al.
Publicado: (2022)

Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End‐Stage Kidney Disease
por: Niu, Chih‐Yuan, et al.
Publicado: (2022)

Evaluating the safety and tolerability of inpatient sacubitril/valsartan initiation in a community hospital
por: Peppin, Katie L., et al.
Publicado: (2020)

Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
por: Khan, Muhammad Nauman, et al.
Publicado: (2023)

Eligibility of sacubitril–valsartan in a real‐world heart failure population: a community‐based single‐centre study
por: Norberg, Helena, et al.
Publicado: (2018)

“Real World” Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry
por: Simpson, Joanne, et al.
Publicado: (2019)

Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study
por: Ganesananthan, Sashiananthan, et al.
Publicado: (2020)

Effect of sacubitril/valsartan or valsartan on ventricular remodeling and myocardial fibrosis in perimenopausal women with hypertension
por: Chen, Jianshu, et al.
Publicado: (2023)

The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant
por: Beck-da-Silva, Luís, et al.
Publicado: (2019)

Practical guidance on the use of sacubitril/valsartan for heart failure
por: Sauer, Andrew J., et al.
Publicado: (2018)

Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma
por: Andersen, Ulrik Ø, et al.
Publicado: (2020)

Effectiveness of sacubitril–valsartan in cancer patients with heart failure
por: Martín‐Garcia, Ana, et al.
Publicado: (2020)

Renin profiling predicts neurohormonal response to sacubitril/valsartan
por: Vergaro, Giuseppe, et al.
Publicado: (2020)

Sacubitril/valsartan in the treatment of systemic right ventricular failure
por: Zandstra, Tjitske E, et al.
Publicado: (2021)

Haemodynamic effects of sacubitril/valsartan in advanced heart failure
por: Gentile, Piero, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cskppvar297usvdv4uceo79kps